The formulation significantly curtailed tumor growth, lowered ascitic volume, and enhanced mean survival time via coordinated regulation of apoptotic (Bax, Bcl-2, Caspase-3) and angiogenic (VEGF) pathways. The gene discussed is CASP3; the disease is neoplasm.